Petros Pharmaceuticals, Inc. PTPI
We take great care to ensure that the data presented and summarized in this overview for Petros Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PTPI
Top Purchases
Top Sells
About PTPI
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Insider Transactions at PTPI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 21
2023
|
Fady Boctor Officer |
BUY
Grant, award, or other acquisition
|
Direct |
49,645
+50.0%
|
-
|
|
Apr 26
2023
|
Bruce Bernstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,050
+42.03%
|
-
|
|
Apr 26
2023
|
Greg Bradley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,050
+42.12%
|
-
|
|
Apr 26
2023
|
Joshua Silverman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,722
+37.43%
|
-
|
|
Apr 26
2023
|
Wayne Remell Walker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,050
+42.12%
|
-
|
|
Jan 20
2023
|
Bruce Bernstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,264
+49.65%
|
-
|
|
Jan 20
2023
|
Greg Bradley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,264
+50.0%
|
-
|
|
Jan 20
2023
|
Joshua Silverman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,515
+35.78%
|
-
|
|
Jan 20
2023
|
Wayne Remell Walker Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,264
+50.0%
|
-
|
|
Dec 22
2021
|
John D Shulman Director |
BUY
Open market or private purchase
|
Indirect |
145,773
+2.49%
|
$437,319
$3.43 P/Share
|
|
Nov 29
2021
|
John D Shulman Director |
BUY
Open market or private purchase
|
Indirect |
500,000
+8.25%
|
$1,500,000
$3.0 P/Share
|
|
Oct 18
2021
|
John D Shulman Director |
BUY
Open market or private purchase
|
Indirect |
1,661,807
+24.73%
|
$1,661,807
$1.72 P/Share
|
|
Dec 01
2020
|
John D Shulman Director |
BUY
Grant, award, or other acquisition
|
Indirect |
3,382,416
+50.0%
|
-
|
|
Dec 01
2020
|
Keith Lavan Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
975
+50.0%
|
-
|
|
Dec 01
2020
|
Andrew Gesek President, Timm Medical |
BUY
Grant, award, or other acquisition
|
Indirect |
97
+50.0%
|
-
|
|
Dec 01
2020
|
Joshua Silverman Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 49.6K shares |
|---|